Publications in collaboration with researchers from French Institute of Health and Medical Research (6)

2025

  1. Assessment of the steady-state drug-drug interactions between dolutegravir and ritonavir-boosted darunavir in adolescents

    AIDS

2023

  1. Nucleoside/nucleotide reverse transcriptase inhibitor sparing regimen with once daily integrase inhibitor plus boosted darunavir is non-inferior to standard of care in virologically-suppressed children and adolescents living with HIV – Week 48 results of the randomised SMILE Penta-17-ANRS 152 clinical trial

    eClinicalMedicine, Vol. 60

2018

  1. Long-term trends in mortality and AIDS-defining events after combination ART initiation among children and adolescents with perinatal HIV infection in 17 middle- and high-income countries in Europe and Thailand: A cohort study

    PLoS Medicine, Vol. 15, Núm. 1

2017

  1. Optimal timing of antiretroviral treatment initiation in HIV-positive children and adolescents: A multiregional analysis from Southern Africa, West Africa and Europe

    International Journal of Epidemiology, Vol. 46, Núm. 2, pp. 453-465

2012

  1. Population pharmacokinetics and maximum a posteriori probability Bayesian estimator of abacavir: Application of individualized therapy in HIV-infected infants and toddlers

    British Journal of Clinical Pharmacology, Vol. 73, Núm. 4, pp. 641-650

2008

  1. Plasma drug concentrations and virologic evaluations after stopping treatment with nonnucleoside reverse-transcriptase inhibitors in HIV type 1-infected children

    Clinical Infectious Diseases, Vol. 46, Núm. 10, pp. 1601-1608